Ascentage Pharma Files 6-K for March 2025
Ticker: AAPG · Form: 6-K · Filed: Mar 12, 2025 · CIK: 2023311
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Ascentage Pharma (ASC) filed a 6-K on 3/12, confirming 20-F filing and China HQ.
AI Summary
Ascentage Pharma Group International filed a Form 6-K on March 12, 2025. This report is for the month of March 2025 and indicates the company is a foreign private issuer filing annual reports under Form 20-F. The filing provides their principal executive office address in Suzhou, Jiangsu, China.
Why It Matters
This filing is a routine update for foreign private issuers, confirming their reporting status and providing essential contact information.
Risk Assessment
Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain material new financial or operational information.
Key Players & Entities
- ASCENTAGE PHARMA GROUP INTERNATIONAL (company) — Registrant
- 0001171843-25-001431 (filing_id) — Accession Number
- 20250312 (date) — Filing Date
- 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (address) — Principal Executive Office
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer?
The filer is ASCENTAGE PHARMA GROUP INTERNATIONAL.
When was this report filed?
The report was filed on March 12, 2025.
Does Ascentage Pharma file annual reports under Form 20-F?
Yes, the filing indicates Ascentage Pharma files or will file annual reports under cover of Form 20-F.
Where is Ascentage Pharma's principal executive office located?
The principal executive office is located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 12, 2025 regarding ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG).